Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Stock Information for Femasys Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Femasys Inc.

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.